In the prostate cancer mouse models, the majority of TFs perturbed in the Pten null mouse exhibit concordant alterations in their activities when the PTEN downstream AKT/mTOR pathway is manipulated genetically or pharmaceutically by the mTOR inhibitor rapamycin. The gene discussed is PTEN; the disease is prostate cancer.